UBS’s Gyre Therapeutics GYRE Stock Holding History

UBS’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-4	Closed	-$16K	–	10507
2014 Q2	$16K	Buy	+4	New	+$13.1K	﹤0.01%	8350

Other funds holding GYRE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS's GYRE Position: Q3 2014 in Review

UBS opened a new position in Gyre Therapeutics (GYRE) in Q3 2014: 2 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #9443 among its holdings. This is a return to the name: UBS previously reported a position in GYRE as recently as Q4 2013.

UBS first reported a position in GYRE in Q4 2013 and has held it in 2 quarters since. 55 funds tracked by Wall St. Rank hold GYRE as of Q3 2014.

UBS held 2 shares of Gyre Therapeutics worth $5K as of Q3 2014.
Gyre Therapeutics was a new UBS position in Q3 2014.
Gyre Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9443 holding.
UBS first reported a position in Gyre Therapeutics in Q4 2013 and has held it in 2 quarters since.
55 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.